Department of Obstetrics and Gynecology (Massachusetts General Hospital)

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Retrieved on: 
Wednesday, November 8, 2023
Patient, Principal, Gynaecology, Masonic Cancer Center, Notifiable disease, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Ovarian cancer, Human, TGF, University, Professor, Inflammation, Gynecologic Oncology (journal), SITC, Immunotherapy, DL2, Disease, Division, NK, Cytokine release syndrome, DRS, Tumor microenvironment, Safety, Society, Recommended maximum intake of alcoholic beverages, Pharmaceutical industry, Medical imaging, Vaccine, Liver, Obstetrics, Cancer

MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy. Data from this study was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota who serves as a Principal Investigator of this trial.

Key Points: 
  • The trial is now in its final expanded dose level, and the Company expects it to be completed in the fourth quarter of 2023.
  • There has been one dose-limiting toxicity experience in this study, but it did not trigger stopping rules.
  • In addition, we believe, perhaps even more importantly, their extensive correlative studies provide valuable evidence that will inform our Phase 2 clinical studies in cancer indications.
  • With these strong results as a foundation, we believe we will be in a position to pivot to initiate our first Phase 2 clinical trial this year.”

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Retrieved on: 
Wednesday, November 1, 2023
Principal, Gynaecology, Masonic Cancer Center, Notifiable disease, Department of Obstetrics and Gynecology (Massachusetts General Hospital), TGF, University, Professor, Inflammation, Gynecologic Oncology (journal), Poster, Immunotherapy, Division, University of Minnesota, Society, Patient, Obstetrics, Cancer

MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota.

Key Points: 
  • MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota.
  • The poster will be presented by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota, a Principal Investigator for this study.
  • Title: Pre-clinical and first-in-human studies of HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in advanced solid tumors
    Presenter: Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota
    The presentation will be available on the Company’s website in the Investors section under Events & Presentations, following the conference.

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Retrieved on: 
Sunday, October 22, 2023
Neoplasm, Research, Gynaecology, Incidence, ESMO, Ovarian cancer, European Society for Medical Oncology, Folate, Congress, Endometrial cancer, Mortality, American Society of Clinical Oncology, NYU Langone Health, STRO, NYU, Society, Death, ECIS, Sutro, ADC, EOC, Spacecraft, Oncology, New York University Grossman School of Medicine, Obstetrics, Safety, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Patient, Neutropenia, SAN, Pharmaceutical industry, Europe 1, EU

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC, in patients with endometrial cancer, in a mini oral presentation at the 2023 European Society For Medical Oncology (ESMO) Congress in Madrid, Spain.

Key Points: 
  • Advanced endometrial cancer is the only gynecologic malignancy with increasing incidence and mortality in both the US and Europe1.
  • Estimated incidence in the EU: 92,746 pts with 23,047 deaths (2022)2 and in the US: 66,000 pts with 13,030 deaths (2023)3.
  • “We are pleased to have the opportunity to present these encouraging early data at ESMO this year,” said Anne Borgman, M.D., Sutro’s Chief Medical Officer.
  • Consistent with previous reported luvelta safety results, the most common adverse event was neutropenia; no new safety signals were observed
    *2: European Cancer Information System (ECIS).

Study Reveals the Need to Expand Maternal Mortality Categorization Beyond Pregnancy-Related Deaths

Retrieved on: 
Wednesday, October 25, 2023
Research, Opioid use disorder, Comorbidity, Maternal health, Department of Obstetrics and Gynecology (Massachusetts General Hospital), SMM, MPH, Black Maternal Health Caucus, Disease, Massachusetts Department of Public Health, Public health, Mortality, Obstetrics and gynaecology, University of California, Boston University School of Public Health, Tufts University School of Medicine, Death, Reproductive Sciences, Hospital, Risk, Pregnancy, University, NIH, Public, ER, Dietary supplement, Birth control, Gynaecology, Doctor of Philosophy, Obstetrics

BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large. Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019. It also identified four times as many pregnancy-associated deaths than pregnancy-related ones and a high rate of hospital contacts (hospital admission, observational stays, and ER visits) for those who ultimately died during pregnancy through one year postpartum.

Key Points: 
  • New Research Shows Prior Hospitalization, Severe Maternal Morbidity, and Opioid Use Disorder Were Key Contributors to Pregnancy-Associated Deaths in Massachusetts from 2002 to 2019.
  • BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large.
  • Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019.
  • There is a clear need to expand the focus of maternal mortality to the much larger group of pregnancy-associated deaths to understand the risk factors and events that lead to many of these preventable deaths."

Switch Health Launches At-Home HPV Test, a First of Its Kind in Canada

Retrieved on: 
Tuesday, September 26, 2023
Cervical cancer, Gynaecology, University, Ipsos-Reid, Obstetrics, COVID-19, Woman, Pharmacy, Privacy, Associate, Risk, Anomaly, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Cancer, Motivation, HPV, Statistics Canada, Disease, Vaccine, Birth control, Health

TORONTO, Sept. 26, 2023 /CNW/ - Switch Health invites women across Canada to take control of their health with the introduction of the first-of-its-kind at-home HPV testing kit.

Key Points: 
  • TORONTO, Sept. 26, 2023 /CNW/ - Switch Health invites women across Canada to take control of their health with the introduction of the first-of-its-kind at-home HPV testing kit.
  • The Switch Health HPV Collection Kit allows for prompt, routine HPV (human papillomavirus) testing from the privacy of their own home.
  • By focusing on HPV testing, we can reduce HPV diagnoses across the province, subsequently lowering the risk of future cervical cancer cases.
  • For more information about the Switch Health HPV at-home test kit, please visit www.switchhealth.ca/hpv to learn more or to purchase a test kit.

First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology

Retrieved on: 
Thursday, September 14, 2023
Women, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Consumer, Clinical Trials, Columbia University, Columbia University Irving Medical Center, Internal bleeding, JADA, RBC, Society, ACOG, Obstetrics, PPH, Trial of the century, Obstetrics and gynaecology, Record, Woman, Multimedia, OGN, Hospital, Bleeding, Patient, Hysterectomy, Department of Obstetrics and Gynecology (Massachusetts General Hospital), ICU, American College, SMM, NYSE, Birth control, Gynaecology, Organon

Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of Obstetrics and Gynecology (ACOG), published the results of the RUBY study ( NCT04995887 ) which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH) with the JADA® System.1 JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.1

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of Obstetrics and Gynecology (ACOG), published the results of the RUBY study ( NCT04995887 ) which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH) with the JADA® System.1 JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230913796173/en/
    “PPH is a potentially life-threatening obstetric emergency that can occur after childbirth and requires timely medical intervention.1,6 Appropriate management of abnormal postpartum uterine bleeding is critical to minimize the potential clinical consequences of PPH7 and its associated severe maternal morbidities, such as the need for blood transfusions, ICU admission or hysterectomy,”1,8,9 said lead author Dena Goffman, M.D., a maternal-fetal medicine subspecialist, and professor and vice chair for quality and patient safety in the Department of Obstetrics and Gynecology at Columbia University Irving Medical Center in New York.
  • “The new study, which included a larger population than the pivotal trial, showed how the device is being used outside of a controlled clinical trial environment.
  • Secondary outcome measures, including time to bleeding control, in-dwelling time, total blood loss and red blood cell transfusions, were also presented.

Former White Sox World Series Champion Massage Therapist Gives Free Access to Award-Winning Video to Help Dads Bond With Their Infants

Retrieved on: 
Wednesday, September 6, 2023
Aurora, 1967 Chicago White Sox season, Obstetrics, Massage, DVD, Chicago White Sox, University, Sleep, Louis, FACOG, Indian Telly Awards, MD, Father, Gynaecology, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Infant, Health, Health care, Amazon

CHICAGO, Sept. 6, 2023 /PRNewswire/ -- John G. Louis, entrepreneur, industry pioneer and former massage therapist of the Chicago White Sox, has today announced free access to his award-winning instructional DVD, "Infant Massage Lessons for Dads.'' The video, produced in 2000 by Chocolate Milk Productions, teaches fathers how to bond with their babies while helping infants to sleep better and foster stronger development. The program won two video excellence awards including the 2004 Aurora Gold Award and the 2005 Telly Award. It is now available for free download on acufore.com and massagewinnetka.com.

Key Points: 
  • CHICAGO, Sept. 6, 2023 /PRNewswire/ -- John G. Louis, entrepreneur, industry pioneer and former massage therapist of the Chicago White Sox, has today announced free access to his award-winning instructional DVD, "Infant Massage Lessons for Dads.''
  • "As a longtime certified massage therapist, I see the value and benefits of massage on health and wellbeing everyday, including for infants," said Louis.
  • Infant Massage Lessons for Dads has empowered millions of dads to learn and practice infant massage since it was first created.
  • Prior to the new free download of Infant Massage Lessons for Dads, the video was sold on Amazon.

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Retrieved on: 
Wednesday, September 6, 2023
Anantara New York Palace Budapest Hotel, Pancreatic cancer, Patent, Masonic Cancer Center, University, University of Minnesota, United States Patent and Trademark Office, Clinical trial, Cancer, Ageing, Gynecologic Oncology (journal), Research, Inflammation, Cell, MRC Laboratory of Molecular Biology, EDT, Trial of the century, Drug resistance, Molecular biology, National Cancer Institute, Professor, Patient, Division, Colorectal cancer, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Immune system, Gynaecology, UMN, Principal, Lotte New York Palace Hotel, NCI, Notifiable disease, Immunosuppression, Natural killer T cell, Laboratory, Conference, Pharmaceutical industry, Vaccine, Obstetrics

On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York.

Key Points: 
  • On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York.
  • In addition, a pre-recorded, virtual Company update will be available on demand beginning at 7:00 a.m. EDT on September 11, 2023 for all who register for the conference.
  • Due to clinical protocol requirements, dosing of the remaining patients is expected to take place in the next 3 to 6 months.
  • Dr. Geller stated, “Our team is very excited to bring this clinical trial to patients who have recurrent cancer.

Texas Children's Pavilion for Women Announces Opening of New Medical Tower

Retrieved on: 
Monday, August 7, 2023
News, Skyway, Obstetrics, Life, Pavilion of Women, Partner, Baylor University, Infertility, Women's Service Guilds, Assistant, U.S. News & World Report, Physical therapy, Memorial Hermann–Texas Medical Center, Hospital, Patient, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Menopause, Gynaecology, Texas Medical Center, Baylor College of Medicine, Growth, Health, Birth control, Pavilion, Woman, Texas Children's Hospital

HOUSTON, Aug. 7, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the newest medical tower, Pavilion for Women Tower II, has opened for patient activity. As the second phase of the $245 million Texas Children's Pavilion for Women's expansion within the Texas Medical Center nears completion, the new tower connected to the Pavilion for Women via a recently constructed sky bridge houses women's services outpatient clinics, including The Women's Specialists of Houston, Partners in OB/GYN Care, and Women's Physical Therapy.

Key Points: 
  • HOUSTON, Aug. 7, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the newest medical tower, Pavilion for Women Tower II, has opened for patient activity.
  • Since opening its doors over a decade ago, the Pavilion for Women has seen rapid growth in the volume of patients seeking labor and delivery services, and the next step of this expansion includes increasing the number of hospital beds in the Texas Children's Pavilion for Women.
  • "I am so proud of everything we've done together and I'm beyond grateful and excited for the continuous growth of Texas Children's Pavilion for Women."
  • Texas Children's is consistently ranked among the best children's hospitals nationally by U.S. News & World Report, and first in Texas.

Lupus Foundation of America Awards Five Summer Fellowship Grants to Young Scientists, Supporting Growth of Lupus Research Field

Retrieved on: 
Monday, July 31, 2023
Lupus Foundation of America, Communication, Yale School of Medicine, Disease, Pregnancy, Deficit spending, Biomedical Research, Research, Mentorship, Lupus, Doctor of Philosophy, Gina, Student, Professor, Patient, Division, Reproductive Sciences, Fellow, Gynaecology, RN, Growth, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Nursing, Management, Obstetrics, Finzi

This program supports mentored research experiences for outstanding undergraduate, graduate and medical students conducting lupus research.

Key Points: 
  • This program supports mentored research experiences for outstanding undergraduate, graduate and medical students conducting lupus research.
  • The program's focus on young scientists is important for cultivating future lupus researchers and growth in the next generation.
  • "The Lupus Foundation of America's Gina M. Finzi Memorial Student Fellowship Program shows our investment in the future minds that will transform lupus research.
  • The research conducted by the awardees will contribute to a wide range of important areas within lupus research: